Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
NCT01314508 · University of California, Los Angeles · NA · withdrawn · last registry update 2026-04-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor has notified us that they are not funding the study” | – | Registry record, University of California, Los Angeles |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-26Results posted on the registry: Sling Therapeutics, Inc., Linsitinib + Placebo (NCT05276063)
- 2026-08-14Results posted on the registry: Viridian Therapeutics, Inc., Veligrotug (NCT06179875)
- 2026-08-13Results posted on the registry: Viridian Therapeutics, Inc., Veligrotug (NCT06384547)
- 2026-08-13Results posted on the registry: Viridian Therapeutics, Inc., Veligrotug + Placebo (NCT05176639)
- 2026-08-13Results posted on the registry: Viridian Therapeutics, Inc., Veligrotug + Placebo (NCT06021054)
- 2026-08-07Phase 3 first posted: Sling Therapeutics, Inc., linsitinib + Placebo (NCT07753603)
- 2026-03-09Results posted on the registry: Lassen Therapeutics Inc., LASN01 + LASN01 (NCT06226545)
- 2025-08-08Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI311 + Placebo (NCT07113262)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision